Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
22.11.2017 16:00:00

Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference

BOULDER, Colo., Nov. 22, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare Conference.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

Event: 

Piper Jaffray Healthcare Conference

Presenter: 

Ron Squarer, Chief Executive Officer

Date: 

Wednesday, November 29, 2017

Time: 

9:00 a.m. Eastern Time

Webcast: 

https://event.webcasts.com/starthere.jsp?ei=1171462&tp_key=889917fd39

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

CONTACT: 

Tricia Haugeto


Array BioPharma Inc.


303-386-1193


thaugeto@arraybiopharma.com

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-2017-piper-jaffray-healthcare-conference-300556111.html

SOURCE Array BioPharma Inc.

Nachrichten zu Array BioPharma Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Array BioPharma Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!